Journal
JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION
Volume 47, Issue 8, Pages 405-408Publisher
ELSEVIER MASSON, CORPORATION OFFICE
DOI: 10.1016/j.jogoh.2018.06.010
Keywords
Immune thrombocytopenia purpura; Eltrombopag; Pregnancy
Categories
Ask authors/readers for more resources
Immune thrombocytopenia (ITP) during pregnancy is an acquired autoimmune disease present in 1-2 of every 1000 pregnancies. Thrombopoietin (TPO)-mimetic drugs, such as eltrombopag, have been successfully used for treatment of ITP during pregnancy, but studies regarding its safety during gestation are lacking. A 33-year-old nulliparous woman with a history of chronic ITP, presented at the emergency department with petechiae, epistaxis, bruises, conjunctival effusions and a platelet count of 3 x 10(9)/L at 25 weeks gestation. Her pregnancy had been uneventful until then. She was unresponsive to a therapeutic escalade of corticosteroids, azathioprine and intravenous immunoglobulin (IV Ig) so, at 27 weeks, eltrombopag was initiated, and analytical and clinical improvement was achieved. Labor was induced at 37 weeks due to preeclampsia, culminating in a vacuum-assisted vaginal delivery. A healthy female newborn weighing 2400 g was born. After delivery, both had normal platelet counts and remained clinically stable through follow-up. (C) 2018 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available